Daunoxome® Treatment of Solid Tumors: Preclinical and Clinical Investigations

Autor:	Michael E. Ross, Eric A. Forssen
Rok vydání:	1994
Předmět:	Liposome Daunorubicin business.industry Cholesterol Pharmaceutical Science Pharmacology Liposomal daunorubicin chemistry.chemical_compound chemistry In vivo Drug delivery medicine Free drug Solid tumor business medicine.drug
Zdroj:	Journal of Liposome Research. 4:481-512
ISSN:	1532-2394 0898-2104
DOI:	10.3109/08982109409037058
Popis:	Daunorubicin has been entrapped into small unilamellar vesicles (50-80 nm dia) composed of a 2:1 mole ratio of highly purified DSPC:cholesterol. In earlier studies, liposomes of this size and composition had been demonstrated to deliver their entrapped contents selectively to a wide range of solid tumors in vivo. Preclinical and initial clinical investigations of these daunorubicin liposomes (DaunoXome) are discussed. In one murine solid tumor model (P1798 lymphosarcoma), a ten-fold increased delivery of entrapped daunorubicin to tumor tissue was observed. Efficacy studies in the same model indicated improved tumor regression and extended life spans that correlated with the observed degree of enhanced tumor drug delivery. In a second tumor model (MA16C mammary adenocarcinoma), a ten-fold enhancement in efficacy again was demonstrated. In terms of median survival times and long term survival rate, DaunoXome dosed at 2 mg/kg (daunorubicin) demonstrated an efficacy comparable to free drug at 20 mg/kg...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::6a65695ee9b52f8472fdc688e726cf4e https://doi.org/10.3109/08982109409037058 Zobrazit plný text záznamu